Wegovy pill achieved approximately 6% weight loss in three months in real-world data

The news headline contains real-world data on the Wegovy pill and is not directly related to GOOGL; its impact on Alphabet's core operations is negligible. Technically, the price at 295.79 is just below the SMA20 (296.33) and above the SMA50 (291.02), indicating a sideways-tight picture in the short term. The RSI at 54 is in neutral territory, and the MACD is below its signal line (1.36 vs 1.93), suggesting weak momentum. The 24-hour 2.97% rise is short-term positive, but confirmation requires MACD recovery and sustained trading above the SMA20. Therefore, I assess the news impact as neutral; there is no clear directional signal.

Real-world data on the oral form of Wegovy shows approximately 6% weight loss in three months, in line with market expectations and presenting a positive picture; this is a mildly positive short-term catalyst for the expansion of NVO's obesity portfolio. The technical picture is also supportive: the price is above the SMA20 and SMA50, the RSI at 62 has not entered overbought territory, and the MACD is positive above its signal line. However, the impact may be limited because the news may be largely priced in and due to competitive pressure in the pharmaceutical sector. In the 1-3 day horizon, a moderate upward trend could strengthen with volume confirmation.

Real-world data showing the Wegovy pill achieves ~6% weight loss in three months indicates increasing competition in the oral GLP-1 market and may somewhat pressure sentiment toward LLY's obesity portfolio. However, since this data pertains to a competitor rather than LLY's own product, the impact may remain limited. On the technical side, the price is above SMA20 and SMA50, with RSI at 61 in neutral-positive territory; MACD is slightly below its signal, momentum weak. Mild news-driven selling pressure is possible in the short term, but the trend is not broken. Confidence is low, as the news does not directly alter LLY's financials.